Tesofensine (NS-2330) is a synthetic small-molecule compound that has been described in the scientific literature within the context of monoamine transporter–associated research. Its characterization is based on biochemical, pharmacological, and observational datasets generated in controlled experimental and preclinical research environments. No therapeutic, diagnostic, or clinical claims are made or implied.

Molecular Formula: C₁₇H₂₃Cl₂NO
Molecular Weight: 327.27 g/mol
PubChem CID: 11370864
CAS Number: 195875-84-4
Alternative Names: Tesofensine, TE, NS-2330

Tesofensine is not a peptide and is structurally classified as a phenyltropane-derived compound. Published sources describe its use as a research compound in studies evaluating monoamine transporter–related biochemical parameters.

Source: PubChem

In research settings, tesofensine has been utilized as an experimental variable in:

• Monoamine transporter binding and uptake assays
• Neurochemical concentration measurements in animal models
• Behavioral and metabolic readout collection under controlled conditions
• Comparative pharmacology studies involving monoamine-associated compounds

All reported applications are limited to laboratory and preclinical research use.

Literature describing tesofensine references observed associations with monoaminergic pathway annotations derived from transporter occupancy data, neurotransmitter concentration profiles, and downstream signaling-related datasets. These descriptions are framed as reported experimental observations rather than asserted biological effects.

• Monoamine transporter–annotated datasets (dopaminergic, noradrenergic, serotonergic)
• Cholinergic pathway–adjacent measurements reported in selected models
• BDNF-annotated gene-expression and protein-level datasets

Preclinical investigations involving tesofensine include rodent-based models in which researchers reported measured endpoints related to neurotransmitter dynamics, behavioral metrics, and metabolic parameters. Transcriptomic and proteomic analyses describe differential expression patterns among neurotrophic and metabolic gene sets under experimental exposure conditions.

Safety-related observations in the literature are reported as trial-level or study-level findings without extrapolation beyond the original experimental context.

This research material is supplied with analytical documentation supporting identity and purity. Standard analytical techniques may include chromatography and mass spectrometry.

1. K. A. Schoedel, D. Meier, B. Chakraborty, P. M. Manniche, and E. M. Sellers, “Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users,” Clin. Pharmacol. Ther., vol. 88, no. 1, pp. 69–78, Jul. 2010, doi: 10.1038/clpt.2010.67.
2. A. Astrup, D. H. Meier, B. O. Mikkelsen, J. S. Villumsen, and T. M. Larsen, “Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease,” Obes. Silver Spring Md, vol. 16, no. 6, pp. 1363–1369, Jun. 2008, doi: 10.1038/oby.2008.56.
3. M. H. Larsen, H. Rosenbrock, F. Sams-Dodd, and J. D. Mikkelsen, “Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine,” Eur. J. Pharmacol., vol. 555, no. 2–3, pp. 115–121, Jan. 2007, doi: 10.1016/j.ejphar.2006.10.029.
4. A. Astrup, S. Madsbad, L. Breum, T. J. Jensen, J. P. Kroustrup, and T. M. Larsen, “Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial,” Lancet Lond. Engl., vol. 372, no. 9653, pp. 1906–1913, 29 2008, doi: 10.1016/S0140-6736(08)61525-1.
5. S. AB, “Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial,” GlobeNewswire News Room, Dec. 17, 2018. https://www.globenewswire.com/news-release/2018/12/17/1667781/0/en/Saniona-s-tesofensine-meets-primary-and-secondary-endpoints-in-Phase-3-obesity-registration-trial.html (accessed Nov. 11, 2021).
6. A. Sjödin et al., “The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men,” Int. J. Obes., vol. 34, no. 11, pp. 1634–1643, Nov. 2010, doi: 10.1038/ijo.2010.87.
7. J.-A. Gilbert, C. Gasteyger, A. Raben, D. H. Meier, A. Astrup, and A. Sjödin, “The effect of tesofensine on appetite sensations,” Obes. Silver Spring Md, vol. 20, no. 3, pp. 553–561, Mar. 2012, doi: 10.1038/oby.2011.197.
8. A. M. D. Axel, J. D. Mikkelsen, and H. H. Hansen, “Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat,” Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol., vol. 35, no. 7, pp. 1464–1476, Jun. 2010, doi: 10.1038/npp.2010.16.
9. H. H. Hansen et al., “The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant,” Eur. J. Pharmacol., vol. 636, no. 1–3, pp. 88–95, Jun. 2010, doi: 10.1016/j.ejphar.2010.03.026.
10. Ł. R. Drzyzga, A. Marcinowska, and E. Obuchowicz, “Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies,” Brain Res. Bull., vol. 79, no. 5, pp. 248–257, Jun. 2009, doi: 10.1016/j.brainresbull.2009.03.009.
11. S. M. Korte et al., “The many different faces of major depression: it is time for personalized medicine,” Eur. J. Pharmacol., vol. 753, pp. 88–104, Apr. 2015, doi: 10.1016/j.ejphar.2014.11.045.
12. D. M. Marks, C.-U. Pae, and A. A. Patkar, “Triple Reuptake Inhibitors: The Next Generation of Antidepressants,” Curr. Neuropharmacol., vol. 6, no. 4, pp. 338–343, Dec. 2008, doi: 10.2174/157015908787386078.
13. B. M. Y. Cheung, T. T. Cheung, and N. R. Samaranayake, “Safety of antiobesity drugs,” Ther. Adv. Drug Saf., vol. 4, no. 4, pp. 171–181, Aug. 2013, doi: 10.1177/2042098613489721.
14. M. George, M. Rajaram, and E. Shanmugam, “New and emerging drug molecules against obesity,” J. Cardiovasc. Pharmacol. Ther., vol. 19, no. 1, pp. 65–76, Jan. 2014, doi: 10.1177/1074248413501017.
15. A. Astrup, S. Madsbad, L. Breum, T. J. Jensen, J. P. Kroustrup, and T. M. Larsen, “Under-reporting of adverse effects of tesofensine,” The Lancet, vol. 382, no. 9887, p. 127, Jul. 2013, doi: 10.1016/S0140-6736(13)61563-9.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.